

October 23, 2026

To,
National Stock Exchange of India Ltd.
Exchange Plaza, BKC
Bandra-Kurla Complex,
Bandra (East), Mumbai-400 051
Symbol: **JLHL**

To,
BSE Limited
P.J. Towers,
25th Floor, Dalal Street, Fort
Mumbai 400 001
Code: **543980**

Subject: Investor Presentation for the quarter and half year ended September 30, 2026.

Reference: Unaudited Financial Results for the quarter and half year ended on September 30, 2026 (Standalone and Consolidated) of the Company.

Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find the enclosed investor presentation for the Unaudited (Standalone and Consolidated) Financial Results for the quarter and half year ended September 30, 2026.

The same will be available on the website of the Company at www.jupiterhospital.com

You are requested to kindly take the afore mentioned on record and oblige.

Thanking you,

For JUPITER LIFE LINE HOSPITALS LIMITED

SUMA
VINAYAK
UPPARATTI

Digitally signed by
SUMA VINAYAK
UPPARATTI
Date: 2026.10.23
16:09:35 +05'30'

Suma Upparatti
Company Secretary & Compliance Officer



CARE THAT
MOVES FORWARD,
EVERY YEAR.

Investor Presentation: October 2026
(Q2 & H1FY27)

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Jupiter Life Line Hospitals Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

This presentation contains certain forward looking statements concerning the Company’s future business prospects and business profitability, which are subject to a number of risks and uncertainties and the actual results could materially differ from those in such forward looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, our ability to manage growth, competition (both domestic and international), economic growth in India and abroad, ability to attract and retain highly skilled professionals, time and cost over runs on contracts, our ability to manage our international operations, government policies and actions regulations, interest and other fiscal costs generally prevailing in the economy. The Company does not undertake to make any announcement in case any of these forward looking statements become materially incorrect in future or update any forward looking statements made from time to time by or on behalf of the Company.



Dr. Ankit Thakker
MD & CEO

Patient First

"I am pleased to share that, following successful negotiations with the landowner, the Board has approved the acquisition of the land currently leased for our Pune South hospital. The land measures 11,452.07 sq. m. and the total consideration is Rs 150 cr. The Rs 50 cr deposit paid earlier will be adjusted against this, so the incremental cash outflow is limited to Rs 100 cr. Owning the land removes long-term lease risk and strengthens our asset base at one of our key growth locations.


Construction at Pune South is progressing well and remains on schedule. The Mira Road and BKC projects are currently in the regulatory approval and planning stages.

Our Dombivli hospital saw a higher infectious-disease burden this quarter, which drove higher occupancy compared with the previous quarter. This helped narrow its EBITDA loss to Rs 0.2 cr for the period. Our other three hospitals continued to perform in line with expectations."



Q2FY27 Performance Highlights

Rs in Cr




- EBITDA impact on account of the new Dombivli hospital was only Rs. 0.2 cr (due to higher medical admissions) in Q2FY27 vs Rs. 9.5 cr in Q1FY27.



H1FY27 Performance Highlights

Rs in Cr




- EBITDA impacted by initial ramp-up losses at Dombivli Hospital of Rs. 9.7 cr in H1FY27 along with higher marketing costs related to launch activities
- Higher depreciation following commercialisation of Dombivli hospital
- Higher finance costs owing to an increase debt drawdown for ongoing capex


H1FY27 Operating Metrics

Operational Bed Capacity⁽¹⁾


Census Beds Non - Census Beds




Average Occupancy Rate⁽²⁾




IPD & OPD Volumes ('000)⁽³⁾




ARPOB⁽⁴⁾



IP ARPOB⁽⁵⁾




ALOS (in Days)⁽⁶⁾



Payor Mix

Government Schemes Self Payors Insurance Companies



ARPOB and IP ARPOB rounded off to the nearest hundred

1) Operational beds includes census beds (bed available for mid-night occupancy such as intensive care units ("ICUs"), wards etc.) and non-census beds (all other bed available other than census beds, such as day-care beds, casualty beds etc.) (2) Average occupancy rate is calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by available census bed days (i.e. census bed capacity multiplied by the applicable days in the relevant period) (3) Out-patient volume refers to the total number of Out-patient bills generated in a specific period. Inpatient volume refers to the total number of inpatient discharge in a specific period irrespective of admission date. (4) ARPOB is calculated as income from hospital services divided by census occupied bed days (i.e. midnight census of occupied census beds during the period) (5) Calculated on Inpatient Revenue divided by Inpatient occupied bed days (excluding daycare) (6) ALOS is the average length of stay of patients in a specific period, calculated as census occupied bed days (i.e. midnight census of occupied census beds during the period) divided by inpatient volume.

Consolidated Profit & Loss Statement

Particulars (in Rs. Crs)	Q2FY27	Q2FY26	YoY	Q1FY27	QoQ	H1FY27	H1FY26	YoY	FY26
Revenue from Operations	436.3	376.8	15.8%	392.6	11.1%	828.8	714.7	16.0%	1,435.6
Other Income - Operational	20.2	16.8		18.4		38.7	31.9		64.2
Total Income	456.5	393.6	16.0%	411.0	11.1%	867.5	746.6	16.2%	1,499.8
Cost of Goods Sold	86.5	73.8		80.0		166.5	144.5		287.3
Gross Profit	370.0	319.8	15.7%	331.0	11.8%	701.0	602.1	16.4%	1,212.5
Gross Profit Margin	81.1%	81.3%		80.5%		80.8%	80.6%		80.8%
Employee Cost	81.3	63.2		74.5		155.8	125.0		256.3
Professional Fees	110.2	103.0		102.2		212.4	185.7		364.0
Other Expenses	71.6	61.4		75.0		146.6	120.8		248.9
EBITDA	106.9	92.2	15.9%	79.3	34.8%	186.2	170.7	9.1%	343.3
EBITDA Margin	23.4%	23.4%		19.3%		21.5%	22.9%		22.9%
Depreciation	28.5	21.5		26.4		54.9	42.7		87.6
EBIT	78.4	70.7	10.9%	52.9	48.2%	131.3	128.0	2.6%	255.6
EBIT Margin	17.2%	18.0%		12.9%		15.1%	17.1%		17.0%
Other Income - Finance	10.5	11.3		10.6		21.1	24.1		42.4
Finance Cost	13.8	7.8		12.9		26.7	16.1		32.7
Exceptional Item Gain / (Loss)*	0.0	0.0		0.0		0.0	0.0		4.9
PBT	75.1	74.2	1.2%	50.6	48.4%	125.7	136.0	-7.6%	260.4
PBT Margin	16.5%	18.9%		12.3%		14.5%	18.2%		17.4%
Tax	18.7	16.8		13.1		31.8	34.6		66.2
PAT	56.4	57.4	-1.7%	37.5	50.4%	93.9	101.4	-7.4%	194.2
PAT Margin	12.4%	14.6%		9.1%		10.8%	13.6%		12.9%
Basic EPS**	1.72	1.75		1.14		2.86	3.09		5.92

- EBITDA includes an operational loss from Dombivli Hospital for Rs 0.2 cr and Rs 9.5 cr for Q2FY27 and Q1FY27 respectively and Rs 9.7 cr in H1FY27 during the initial ramp-up phase
- Depreciation has increased due to capitalisation of newly added beds
- Higher finance costs owing to an increase debt drawdown for ongoing capex

Consolidated Balance Sheet

Equity & Liabilities (in Rs. Crs)	Sep-26	Mar-26
Total Equity	1,630.5	1,544.1
Share Capital	65.6	65.6
Other Equity	1,564.7	1,478.5
Non-Controlling interest	0.2	0.0
Non-Current Liabilities	683.3	612.5
Financial Liabilities		
Borrowings	565.5	500.9
Lease liabilities	68.9	65.5
Provisions	17.9	16.5
Deferred Tax Liabilities	31.0	29.6
Current Liabilities	246.3	226.5
Financial Liabilities		
Borrowings	23.3	7.6
Lease liabilities	10.9	10.2
Trade Payables	65.1	95.5
Other financial Liabilities	96.3	70.9
Other Current Liabilities	31.9	29.7
Current tax liabilities (net)	4.0	3.4
Provisions	14.8	9.2
Total Equity & Liabilities	2,560.1	2,383.1

Assets (in Rs. Crs)	Sep-26	Mar-26
Non - Current Assets	1,945.4	1,698.2
Property Plant & Equipments	1,320.7	1,276.8
Right of use assets	103.7	99.1
CWIP	193.8	129.2
Goodwill	5.1	0.0
Other Intangible assets	9.4	8.0
Financial Assets		
Investments	0.1	0.1
Other Financial Assets	34.6	33.2
Deferred tax assets (net)	19.5	19.8
Other Non - Current Assets (Net)	258.5	132.0
Current Assets	614.7	684.9
Inventories	35.8	38.3
Financial Assets		
Investments	384.7	485.7
Trade receivables	118.3	75.5
Cash and cash equivalents	45.1	54.8
Bank balances other than above	1.7	3.4
Other financial assets	0.2	6.5
Current tax assets (net)	9.7	6.5
Other Current Assets	19.2	14.2
Total Assets	2,560.1	2,383.1

Consolidated Cash Flow Statement

Particulars (in Rs. Crs)	H1FY27	H1FY26
Net Profit Before Tax	125.6	136.0
Adjustments for: Non -Cash Items / Other Investment or Financial Items	65.4	41.6
Operating profit before working capital changes	191.0	177.6
Changes in working capital	-22.6	-13.6
Cash generated from Operations	168.4	164.0
Direct taxes paid (net of refund)	-32.3	-33.8
Net Cash from Operating Activities	136.1	130.2
Net Cash from Investing Activities	-176.3	-173.2
Net Cash from Financing Activities	28.4	-23.3
Net Decrease in Cash and Cash equivalents	-11.8	-66.3
Add: Cash & Cash equivalents at the beginning of the period	56.9	92.5
Cash & Cash equivalents at the end of the period	45.1	26.2

Next-Phase of Growth: Scaling Bed Capacity from 1,700 to 2,900

Hospitals	Bed Capacity	Capex/Bed (Excl. Land) (Rs in cr)	Expected to be operational	Remarks
Recently Commissioned				
Dombivli	500	Phase-wise commissioning underway, with ~200 beds operational and fit-outs completed for an additional 100 beds		
Greenfield				
Pune II	500	1.2	CY28	Under construction
Mira - Bhayandar	300	1.3	CY29	Project currently at conceptualization and planning stage
BKC	400	1.5	CY31	Documentation & registration

Strong post IPO Expansion of ~1,700 beds at an Average Cost/Bed of ~ **Rs 1.5 Cr***

Strategic Priorities Behind Expansion

- ✓ Strategic land bank in high-demand micro markets
- ✓ Phased commissioning to optimize capital deployment
- ✓ Strong operating leverage from consolidated scale

*Including land cost



Jupiter Life Line Hospitals Limited

CIN: L85100MH2002PLC137908

investor.relations@jupiterhospital.com



Strategic Growth Advisors Pvt. Ltd.

CIN: U74140MH2010PTC204285

Mandar Chavan / Rahul Agarwal
mandar.chavan@sgapl.net / rahul.agarwal@sgapl.net
+91 96993 82195 / +91 98214 38864

Thank You